Search Results for: Organigram
Organigram Announces C$124.6 Million Investment from BAT and Creation of “Jupiter” Strategic Investment Pool
Organigram and BAT deepen partnership through C$124.6 million investment with 38.7 million shares to be…
Organigram Reports Third Quarter Fiscal 2023 Results
Year-to-date Canadian recreational business grew 10% versus prior year driven by continued focus on consumer-centric…
Organigram Announces Completion of Share Consolidation
Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI) announced today that, further…
Organigram Makes First Strategic U.S. Investment in Phylos Bioscience to Commercialize THCV and Scale Seed Based Production
Phylos is a recognized leader in seed genetics with a growing IP portfolio including the…
Organigram to Enter German Market Supplying Sanity Group
Organigram to supply the medical division of German cannabis company Sanity Group with high-quality medical…
Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”), a leading Canadian licensed producer of…
Organigram Reports Second Quarter Fiscal 2022 Results
HIGHLIGHTS Achieved gross revenue of $43.9 million, up 128% from the same prior-year period and…
Organigram to Report Second Quarter 2022 Results on April 12, 2022
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the…
Organigram Reports First Quarter Fiscal 2022 Results
$30.4 million net revenue represents a record for the Company as it solidifies #4 market…
Organigram Reports Fourth Quarter Fiscal 2021 Results
Continued growth in net revenue and increased market share Achieved a 7% share of market…
Recent Comments